

**SPH.L**

### **Convertible Unsecured Loan Notes**

6<sup>th</sup> September 2010, Godalming, UK: Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, is pleased to announce that the Company has refinanced the £2.3 million convertible unsecured loan notes that expired on 3 September 2010 through the issue of a new series of £2.3 million loan notes (the "2010 Notes") placed with the same institutional investor and on the same terms as the expiring notes.

**Ends**

**For further information please contact:**

**Sinclair Pharma plc**  
Chris Spooner, CEO  
Alan Olby, CFO

Tel: +44 (0) 1483 410 600

**Singer Capital Markets Ltd**  
Shaun Dobson  
Claes Spång

Tel: +44 (0)20 3205 7500

**Biddicks, Financial Public Relations**  
Shane Dolan

Tel: +44 (0)20 7448 1000

#### **Summary of the 2010 Loan Notes**

- The 2010 Notes are unsecured and carry a coupon of 8per cent. Payable quarterly in arrears
- The 2010 Notes can be converted at 24.68pence, the same price as the expiring notes
- The 2010 Notes convert into ordinary shares of 1 pence each ranking pari passu with the existing ordinary shares
- The 2010 Notes can be converted on quarter end days commencing on 31 December 2010, up to 31 March 2012
- The 2010 Notes expire and will be repaid on 31 March 2012 in the event that they have not previously been converted

#### **Notes to Editors:**

**About Sinclair Pharma Plc** [www.sinclairpharma.com](http://www.sinclairpharma.com)

Sinclair Pharma plc is an international, highly commercial, rapid-growth dermatology and oral care company providing and promoting high quality and differentiated products through growing sales and marketing operation that is present in France, Italy, Germany and Spain, and through an extensive marketing partner network across selected developed & emerging markets.

*"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.*